

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD
QUAKERBRIDGE PLAZA, BUILDING 7, Rooms 200 ABC**

October 24, 2012

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

AGENDA

I. Call to order in accordance with New Jersey Open Public Meeting Act

II. Roll Call

III. Review of draft meeting summary for June 27 meeting (pages 3-6; Tab 1)

IV. Secretary's report (pages 7-8; Tab 2)

V. Old Business

1. Short-acting opioids utilization Jan – Jun 2012 (pages 9-10; Tab 3)

VI. New Business

- A. Proposed protocol for low dose quetiapine (Seroquel[®]) (pages 11-14; Tab 4)
- B. Proposed protocol for the efficient use of medications in HIV pre-exposure prophylaxis (pages 15-16; Tab 5)

VII. Informational Highlights/Reports

1. Molina Prior Authorization Report (pages 17-18; Tab 6)
 - (a) Duration exceeded denial outcomes (pages 19-20; Tab 6)
2. NJ HMO Reports 2nd Quarter 2012 (pages 21-24; Tab 7)
3. DHS Top Drugs Report
 - a. Monthly Top Drugs Report (pages 25-37; Tab 8)
 - b. Quarterly Top Drugs -Net Cost (pages 38-50; Tab 8)
4. FDA Alerts (pages 51-55; Tab 9)
 - (a) FDA approved Belviq[®] (lorcaserin) to treat some overweight or obese adults
 - (b) FDA approved Qsymia[®] (phentermine and topiramate ER) for weight management
 - (c) FDA approved Stribild[®], new combination pill, for HIV treatment